AU2008282032B2 - Novel heterocyclic compounds as mGlu5 antagonists - Google Patents

Novel heterocyclic compounds as mGlu5 antagonists Download PDF

Info

Publication number
AU2008282032B2
AU2008282032B2 AU2008282032A AU2008282032A AU2008282032B2 AU 2008282032 B2 AU2008282032 B2 AU 2008282032B2 AU 2008282032 A AU2008282032 A AU 2008282032A AU 2008282032 A AU2008282032 A AU 2008282032A AU 2008282032 B2 AU2008282032 B2 AU 2008282032B2
Authority
AU
Australia
Prior art keywords
pyridyl
piperidine
prop
methyl
ynylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2008282032A
Other languages
English (en)
Other versions
AU2008282032A1 (en
Inventor
Davide Graziani
Amedeo Leonardi
Matteo Marco Longhi
Gianni Motta
Elena Poggesi
Carlo Riva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati Ireland Ltd
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of AU2008282032A1 publication Critical patent/AU2008282032A1/en
Application granted granted Critical
Publication of AU2008282032B2 publication Critical patent/AU2008282032B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008282032A 2007-08-02 2008-08-01 Novel heterocyclic compounds as mGlu5 antagonists Expired - Fee Related AU2008282032B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95367707P 2007-08-02 2007-08-02
US60/953,677 2007-08-02
US4517508P 2008-04-15 2008-04-15
US61/045,175 2008-04-15
PCT/EP2008/006351 WO2009015897A1 (en) 2007-08-02 2008-08-01 Novel heterocyclic compounds as mglu5 antagonists

Publications (2)

Publication Number Publication Date
AU2008282032A1 AU2008282032A1 (en) 2009-02-05
AU2008282032B2 true AU2008282032B2 (en) 2014-08-07

Family

ID=39885225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008282032A Expired - Fee Related AU2008282032B2 (en) 2007-08-02 2008-08-01 Novel heterocyclic compounds as mGlu5 antagonists

Country Status (22)

Country Link
US (1) US8518916B2 (https=)
EP (1) EP2178858B1 (https=)
JP (1) JP5412430B2 (https=)
KR (1) KR20100052507A (https=)
CN (1) CN101821256A (https=)
AT (1) ATE539075T1 (https=)
AU (1) AU2008282032B2 (https=)
BR (1) BRPI0814182A2 (https=)
CA (1) CA2694359A1 (https=)
CY (1) CY1112500T1 (https=)
DK (1) DK2178858T3 (https=)
EA (1) EA018328B1 (https=)
ES (1) ES2380165T3 (https=)
HR (1) HRP20120225T1 (https=)
IL (1) IL203659A (https=)
NZ (1) NZ582934A (https=)
PL (1) PL2178858T3 (https=)
PT (1) PT2178858E (https=)
RS (1) RS52167B (https=)
SI (1) SI2178858T1 (https=)
WO (1) WO2009015897A1 (https=)
ZA (1) ZA201001467B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089119A1 (en) * 2009-02-04 2010-08-12 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
US20120028931A1 (en) * 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
WO2012085166A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
CN104011016B (zh) * 2011-12-27 2016-08-17 帝斯曼知识产权资产管理有限公司 维生素a中间体的催化合成
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
WO2014039049A1 (en) * 2012-09-07 2014-03-13 Empire Technology Development Llc Regioregular copolymers and methods for making same
AU2014211727B2 (en) * 2013-02-04 2018-07-26 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3
CA3066193A1 (en) * 2017-06-29 2019-01-03 Recordati Industria Chimica E Farmaceutica Spa Heterocyclylmethylidene derivatives and their use as modulators of mglur5 receptors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186292A1 (en) * 2002-05-28 2004-09-23 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24826E (en) * 1956-08-30 1960-05-17 N-alkylpiperidyl alkynylamines
JPS5995249A (ja) * 1982-11-24 1984-06-01 Ono Pharmaceut Co Ltd ロイコトリエンｂ４類似化合物、その製造方法及びそれらを有効成分として含有する治療剤
EP0537993A1 (en) * 1991-10-17 1993-04-21 Eli Lilly And Company Nicotinic activity of a series of arecolones and isoarecolones
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
AP2005003199A0 (en) * 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6265434B1 (en) * 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
ITMI991452A1 (it) * 1999-07-01 2001-01-01 Mediolanum Farmaceutici Srl Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
US6387909B1 (en) * 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306861B1 (en) * 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
US6548522B1 (en) 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
US6403594B1 (en) * 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
US6365591B1 (en) * 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US6369222B1 (en) * 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
WO2004041777A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
US7572922B2 (en) * 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
US7338954B2 (en) * 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
WO2005097760A1 (en) 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
US8334290B2 (en) * 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
KR101495611B1 (ko) * 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
US7985754B2 (en) 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186292A1 (en) * 2002-05-28 2004-09-23 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides

Also Published As

Publication number Publication date
DK2178858T3 (da) 2012-03-19
EP2178858A1 (en) 2010-04-28
JP2010535165A (ja) 2010-11-18
CY1112500T1 (el) 2015-12-09
WO2009015897A1 (en) 2009-02-05
NZ582934A (en) 2011-10-28
BRPI0814182A2 (pt) 2015-01-27
EA201000283A1 (ru) 2010-06-30
ES2380165T3 (es) 2012-05-09
RS52167B (sr) 2012-08-31
AU2008282032A1 (en) 2009-02-05
ATE539075T1 (de) 2012-01-15
CA2694359A1 (en) 2009-02-05
HK1141788A1 (en) 2010-11-19
ZA201001467B (en) 2010-11-24
EA018328B1 (ru) 2013-07-30
US20090042841A1 (en) 2009-02-12
CN101821256A (zh) 2010-09-01
JP5412430B2 (ja) 2014-02-12
EP2178858B1 (en) 2011-12-28
KR20100052507A (ko) 2010-05-19
US8518916B2 (en) 2013-08-27
HRP20120225T1 (hr) 2012-04-30
SI2178858T1 (sl) 2012-03-30
IL203659A (en) 2013-06-27
PT2178858E (pt) 2012-02-24
PL2178858T3 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
AU2008282032B2 (en) Novel heterocyclic compounds as mGlu5 antagonists
JP6800325B2 (ja) オートタキシン阻害剤としての新規化合物及びそれらを含む医薬組成物
CA2560689C (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
JP5820538B2 (ja) 認知症の統合失調症の治療のためのｍＧｌｕ５受容体活性のアロステリックモジュレーターとしての１，２，４−トリアゾール
US20090069340A1 (en) Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
JP2021522253A (ja) 化合物及びその使用
US9062033B2 (en) Chemical compounds
MX2011001090A (es) Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
JP2004277337A (ja) ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2015066697A1 (en) Fused morpholinopyrimidines and methods of use thereof
WO2009081259A1 (en) Phenoxy-pyridyl derivatives
CA2623154A1 (en) Novel fused pyrrole derivative
AU2011275696B2 (en) Novel spiroheterocyclic compounds as mGlu5 antagonists
EP2632924A1 (en) Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists
TW202028188A (zh) 新穎胺基-嘧啶酮基-哌啶基衍生物、其製備之方法及包含其之醫藥組合物
US20120028931A1 (en) Heterocyclic m-glu5 antagonists
HK1141788B (en) Novel heterocyclic compounds as mglu5 antagonists
US20100317630A1 (en) Novel heterocyclic compounds as mglu5 antagonists
JPH10226689A (ja) 縮合型イミダゾピリジン誘導体、その製造法及び剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application